Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-29
$62.48+1.78%
Close 2026-10-30 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-29
Research Workspace
Put BMY beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 4% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 13%.
View QualityManagement screens strong on capital allocation, earnings delivery, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
BMY’s case rests on strong recent financial performance and growth medicines supporting higher 2026 guidance. Revenue growth accelerated from 3% to 7%, and Q3 2026 non-GAAP EPS beat consensus. BMY trades at 10× P/E versus the 16× peer median. The price reflects less growth than our forecast, despite that valuation gap. The specific risk is the announced $1.5B-$2B Eliquis step-down in 2027. Our model puts the next-quarter miss probability near 11%. Peer multiples imply a price about 7% below where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. BMY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 30 analysts currently covering BMY (as of Oct 2026).
Based on 13 Wall Street analysts offering 12-month price targets for BMY in the last 4 months.
Continue this research
Compare BMY with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BMY Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put BMY next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Raise full-year revenue and EPS guidance for 2026
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $62.48
The last 12 months of price, then the range of analyst 12-month targets from today’s $62.48.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
2026 EPS outlook supports guidance-raising objective despite the anticipated 2027 Eliquis decline.
Advances: Raise full-year revenue and EPS guidance for 2026
Higher quarterly revenue and raised outlook support the 2026 guidance objective.
Advances: Raise full-year revenue and EPS guidance for 2026
Reported Q3 beat and higher revenue outlook support the 2026 guidance objective.
Advances: Advance pipeline with high-impact transformational medicines
Reported efficacy signal supports pipeline progress, though the headline alone lacks trial and source details.
Advances: Advance pipeline with high-impact transformational medicines
Encouraging global Phase 2 data supports pipeline progress, though efficacy remains early-stage.
Advances: Advance pipeline with high-impact transformational medicines
Late-stage lower-dose lung disease trial success advances pipeline and supports a potential growth asset.
Advances: Advance pipeline with high-impact transformational medicines
BMY trial win lifted partner Contineum and supports development progress in a pipeline asset.
Advances: Advance pipeline with high-impact transformational medicines
Two phase 3 successes are meaningful pipeline validation and potential future growth.